The core team of the company comes from Peking
University, Tsinghua University, Harvard University, University of
California, Berkeley and other famous universities
or research institutions at home and abroad.
Founded in 2021, the company is dedicated to providing scale-up, low-cost stem cell therapy solutions for a range of major degenerative diseases for which no clinical solutions exist.
Patients first, "Blade" second, shareholders third.
In May 2021, XellSmart Bio officially announced the establishment.
近億元Pre-A輪融資，啟明創(chuàng )投和禮來(lái)亞洲共同領(lǐng)投
COPYRIGHT? 2021
